The researchers studied 37,732 positive COVID-19 cases among healthcare workers between March 27 and June 4, when omicron subvariant BA.2 was dominant in Canada and most positive tests were assumed to be BA.2 infections.
Of the workers who were vaccinated with either Pfizer’s or Moderna’s mRNA-based doses and likely had BA.1, their risk of another infection fell 96 percent, according to the study. Unvaccinated individuals who had a presumed BA.1 infection have a 72 percent risk reduction, and vaccinated people who have not had COVID-19 have a 46 percent risk reduction.
The lowest protective factor for future infection was having a previous, pre-omicron COVID-19 case, which garnered a 38 percent risk reduction.
Because there wasn’t a measurable difference in risk reduction between a second and a third COVID-19 vaccine, the researchers concluded additional doses should be prioritized for “people who are more vulnerable globally.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
